As if the talc product liability lawsuits weren’t enough headache for Johnson & Johnson, the New Jersey pharma is now facing another lawsuit from patients, this time about a recent data breach. J&J ...
Johnson & Johnson’s attempt to develop a $5 billion-a-year Alzheimer’s disease drug has been rocked by a phase 2 flop. A scheduled data review found the anti-tau antibody posdinemab failed to ...
Economists on the left and right criticized E.J. Antoni for misunderstanding the data he would now oversee. By Ben Casselman Alan Rappeport and Lydia DePillis On Aug. 1, shortly after the Bureau of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback